These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18201149)

  • 41. Effects of macrolides and ketolides on mycobacterial infections.
    Bermudez LE; Yamazaki Y
    Curr Pharm Des; 2004; 10(26):3221-8. PubMed ID: 15544511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ketolides: the future of the macrolides?
    Nilius AM; Ma Z
    Curr Opin Pharmacol; 2002 Oct; 2(5):493-500. PubMed ID: 12324249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Binding site of the bridged macrolides in the Escherichia coli ribosome.
    Xiong L; Korkhin Y; Mankin AS
    Antimicrob Agents Chemother; 2005 Jan; 49(1):281-8. PubMed ID: 15616307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.
    Nicolau DP
    Expert Opin Pharmacother; 2004 Feb; 5(2):229-35. PubMed ID: 14996620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Telithromycin].
    Benes J
    Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.
    Ma CX; Lv W; Li YX; Fan BZ; Han X; Kong FS; Tian JC; Cushman M; Liang JH
    Eur J Med Chem; 2019 May; 169():1-20. PubMed ID: 30852383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cethromycin: a promising new ketolide antibiotic for respiratory infections.
    Rafie S; MacDougall C; James CL
    Pharmacotherapy; 2010 Mar; 30(3):290-303. PubMed ID: 20180612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.
    Shi J; Montay G; Bhargava VO
    Clin Pharmacokinet; 2005; 44(9):915-34. PubMed ID: 16122280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Telithromycin (Ketek) for respiratory infections.
    Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
    [No Abstract]   [Full Text] [Related]  

  • 52. Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics.
    Bonnefoy A; Le Priol P
    J Antimicrob Chemother; 2001 Apr; 47(4):471-3. PubMed ID: 11266424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
    Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV; Brown SD
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Giovanetti E; Montanari MP; Marchetti F; Varaldo PE
    J Antimicrob Chemother; 2000 Dec; 46(6):905-8. PubMed ID: 11102408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae.
    Champney WS; Mentens N; Zurawick K
    Curr Microbiol; 2004 Oct; 49(4):239-47. PubMed ID: 15386111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Macrolides, ketolides and streptogramins].
    Mensa J; García-Vázquez E; Vila J
    Enferm Infecc Microbiol Clin; 2003 Apr; 21(4):200-7; quiz 208, 219. PubMed ID: 12681133
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Telithromycin.
    Spiers KM; Zervos MJ
    Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ketolides-telithromycin, an example of a new class of antibacterial agents.
    Bryskier A
    Clin Microbiol Infect; 2000 Dec; 6(12):661-9. PubMed ID: 11284926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D; Zhanel G; Hoban D
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.